Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Morawska

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
International Journal of Cancer|January 24, 2023
Molnupiravir is effective in patients with haematological malignanciesŁukasz Bołkun, Bartosz Pula, Agnieszka Kołkowska-Leśniak, et al.
Annals of Hematology|July 1, 2023
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study GroupAnita Soboń, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, et al.
Scientific Reports|July 30, 2025
Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomesAgnieszka Giza, Paulina Dumnicka, Elżbieta Kalicińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.
British Journal of Haematology|February 18, 2026
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myelomaKrzysztof Jamroziak, Dominik Dytfeld, Tadeusz Kubicki, et al.
Oncotarget|August 17, 2016
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapyDominik Dytfeld, Magdalena Luczak, Tomasz Wrobel, et al.
Contemporary Oncology (Poznan, Poland)|May 7, 2025
Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study GroupOktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, et al.
Contemporary Oncology (Poznan, Poland)|October 16, 2025
Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study GroupOktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|January 5, 2023
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research GroupEwa Paszkiewicz-Kozik, Iwona Hus, Monika Palka, et al.
Cancers|February 15, 2022
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic LeukemiaBartosz Puła, Katarzyna Pruszczyk, Ewa Pietrusza, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|January 24, 2023
Molnupiravir is effective in patients with haematological malignanciesŁukasz Bołkun, Bartosz Pula, Agnieszka Kołkowska-Leśniak, et al.
Annals of Hematology|July 1, 2023
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study GroupAnita Soboń, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, et al.
Scientific Reports|July 30, 2025
Retrospective analysis of primary pulmonary lymphoma cases from Polish Lymphoma Research Group centers reveals associations between initial symptoms and outcomesAgnieszka Giza, Paulina Dumnicka, Elżbieta Kalicińska, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.
British Journal of Haematology|February 18, 2026
Daratumumab or active observation for asymptomatic biochemical relapse in patients with multiple myelomaKrzysztof Jamroziak, Dominik Dytfeld, Tadeusz Kubicki, et al.
Oncotarget|August 17, 2016
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapyDominik Dytfeld, Magdalena Luczak, Tomasz Wrobel, et al.
Contemporary Oncology (Poznan, Poland)|May 7, 2025
Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study GroupOktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, et al.
Contemporary Oncology (Poznan, Poland)|October 16, 2025
Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study GroupOktawia Sośnia, Elżbieta Iskierka-Jażdżewska, Anna Puła, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|January 5, 2023
Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research GroupEwa Paszkiewicz-Kozik, Iwona Hus, Monika Palka, et al.
Cancers|February 15, 2022
Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic LeukemiaBartosz Puła, Katarzyna Pruszczyk, Ewa Pietrusza, et al.
Pageof 6